| Literature DB >> 28855373 |
Ya-Qun Zhou1, Dai-Qiang Liu1, Shu-Ping Chen1, Jia Sun1, Xue-Rong Zhou1, Fang Luo1, Yu-Ke Tian1, Da-Wei Ye2.
Abstract
Chronic pain, often defined as any pain lasting more than 3 months, is poorly managed because of its multifaceted and complex mechanisms. Calcium/calmodulin-dependent protein kinase II (CaMKII) is a multifunctional serine/threonine kinase that plays a fundamental role in synaptic plasticity, learning, and memory. Recent emerging evidence demonstrates increased expression and activity of CaMKII in the spinal cord and dorsal root ganglia of various chronic pain models. Moreover, our previous studies also find that inhibiting CaMKII could attenuate inflammatory pain and neuropathic pain. In this review, we provide evidence for the involvement of CaMKII in the initiation and development of chronic pain, including neuropathic pain, bone cancer pain, and inflammatory pain. Novel CaMKII inhibitors with potent inhibitory effect and high specificity may be alternative therapeutic strategies for the management of chronic pain in the future.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28855373 DOI: 10.1124/jpet.117.243048
Source DB: PubMed Journal: J Pharmacol Exp Ther ISSN: 0022-3565 Impact factor: 4.030